Rechallenge of programmed cell death 1 inhibitor after an interval with dacarbazine treatment may be effective for advanced malignant melanoma.

Kan, Takanobu; Takahagi, Shunsuke; Kawai, Mikio; Matsubara, Daiki; Tanaka, Akio; Hide, Michihiro

Kan, Takanobu; Takahagi, Shunsuke; Kawai, Mikio; Matsubara, Daiki; Tanaka, Akio; Hide, Michihiro.

Afiliação

Kan T; Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Takahagi S; Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kawai M; Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Matsubara D; Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Tanaka A; Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hide M; Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

J Dermatol ; 47(8): 907-910, 2020 Aug.

Article em En | MEDLINE | ID: mdl-32515012

Assuntos

Melanoma; Neoplasias Cutâneas; Apoptose; Dacarbazina/uso terapêutico; Humanos; Melanoma/tratamento farmacológico; Nivolumabe; Neoplasias Cutâneas/tratamento farmacológico

Palavras-chave

bridging therapy; dacarbazine; malignant melanoma; programmed death 1 inhibitor; rechallenge

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Melanoma Limite: Humans Idioma: En Revista: J Dermatol Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google